Celaid Therapeutics announced an additional JPY 400 million in the second close of its Series B. The release appeared on 5 October 2026 in Amsterdam time, following publication late on 4 October in US Eastern time. Shionogi and Teikoku Ventures are named investors, with no lead explicitly stated. The Tokyo company develops stem-cell therapies for severe diseases, with the financing supporting development and preparations for clinical studies in the United States. The amount refers to the incremental second close, rather than the entire Series B total. Celaid's investment story combines a therapeutic programme with capital supporting its next development stages.
Celaid Therapeutics adds JPY 400m in Series B second close
The new tranche supports stem-cell therapy development

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


